Amine Pharma
Amine Pharma is a Chiba, Japan-based biotech firm that commercialized the world's first blood-based brain infarction risk marker (A6C), distributing the ~85%-accuracy test through 100+ medical institutions and nine clinical laboratory partners to health insurance unions, corporate wellness programs, and adults aged 50+.
- Company typePrivate
- Founded2009
- HeadquartersChiba, Japan
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
What Amine Pharma does
Amine Pharma Research Institute (株式会社アミンファーマ研究所) is a privately held Japanese biotechnology company founded in 2007 (with its core service launching in 2009) and headquartered in Chiba, Japan. It has developed the A6C cerebral infarction risk marker, described as the world's first blood-based biomarker for detecting silent (asymptomatic) brain infarction, which achieves approximately 85% accuracy by measuring acrolein-protein conjugates, IL-6, and CRP in blood and stratifying patients into low-risk, borderline, and high-risk tiers. The technology originated from a long-standing industry-academia collaboration with Chiba University Graduate School of Pharmaceutical Sciences and Chiba Science University, and has been validated through peer-reviewed publications in journals including Atherosclerosis and Stroke, as well as a 7-year longitudinal study at a health insurance union showing brain infarction cases reduced to approximately one-third.
The company's business model is a per-test service fee structure delivered through a B2B2C channel: medical institutions (100+ across Japan) order the A6C test either as a standalone "simple type" examination or as an optional add-on to comprehensive health checkups (人間ドック) or brain-specific examinations (脳ドック), with samples processed by nine clinical testing laboratory partners (including SRL, BML, Koto Biseibutsu Kenkyuujo, Medic, Sanritsu, Alp, Saitama Higashiwa Yakuhin, Hoken Kagaku Kenkyuujo, and Nihon Igan Rinshou Kenkyuujo). End customers are adults aged 50 and older (often through health insurance union or corporate wellness programs), with pricing varying by institution and a 6,000 yen promotional price available through the Chiba City Human Resource Development Support Catalog. Government recognition includes MEXT Minister's Award for Science and Technology (2017), METI Industry-Academia-Government Collaboration Achievement Award (2014), NEDO commercialization recognition, and Kanagawa Prefecture ME-BYO BRAND certification. Beyond the core diagnostic service, Amine Pharma is developing a urinary-biomarker-based dementia risk assessment and a pre-clinical cerebral infarction suppressing compound, signaling an intent to expand from single-product diagnostics into a broader neurology franchise.
Amine Pharma firmographics
Firmographics- Name
- Amine Pharma
- Legal name
- 株式会社アミンファーマ研究所
- Website
- https://amine-pharma.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Amine Pharma is a Chiba, Japan-based biotech firm that commercialized the world's first blood-based brain infarction risk marker (A6C), distributing the ~85%-accuracy test through 100+ medical institutions and nine clinical laboratory partners to health insurance unions, corporate wellness programs, and adults aged 50+.
- Ownership category
- akta.pro rank
Where Amine Pharma is headquartered
LocationHeadquarters
- HQ city
- Chiba
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
Amine Pharma business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Brain Infarction Risk Assessment Testing: Revenue generated from providing brain infarction risk assessment tests through medical institutions. Tests are offered as standalone "simple type" examinations or as optional add-ons to health checkup programs. Clinical testing companies process samples and handle billing with medical institutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard pricing at medical institutions |
| Unit Pricing | Pay-as-you-go | Chiba City subsidized price |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Amine Pharma product offering
Product offeringCore offering
Amine Pharma operates the Cerebral Infarction Risk Assessment Service (A6C), a proprietary blood-based diagnostic that detects silent (asymptomatic) cerebral infarction with approximately 85% accuracy by measuring toxic acrolein, IL-6, and CRP levels and classifying patients into three risk tiers (low-risk, borderline, high-risk). The service is offered through partnered medical institutions and clinical testing laboratories as a standalone "Simple Type" test or as an add-on to comprehensive health checkups (人間ドック) and brain-specific examinations (脳ドック), and is also sold in bulk to corporate wellness programs and health insurance unions.
Product overview
Amine Pharma offers a single core service — the Cerebral Infarction Risk Assessment (A6C) — a blood-based diagnostic tool developed in partnership with Chiba University. The service measures acrolein-conjugated proteins (A6C), IL-6, and CRP in blood to detect silent cerebral infarction and classify patients into three risk tiers. The company also provides downloadable explanatory materials for patients and medical institutions. In addition, Amine Pharma is developing a urinary biomarker-based Dementia Risk Assessment service and a Cerebral Infarction Suppressing Compound for therapeutic use.
Differentiator
Problem solved
Functional benefit
Products and services
- Cerebral Infarction Risk Assessment Service (A6C) A blood-test-based diagnostic service that detects silent (asymptomatic) cerebral infarction and assesses cerebral infarction risk with approximately 85% accuracy. It measures blood levels of acrolein (a cytotoxic compound), IL-6, and CRP to classify patients into three risk tiers (low-risk, borderline, high-risk). The service is delivered through partnered medical institutions (hospitals and clinics) and clinical testing laboratories, and is targeted at adults aged 50 and older, corporate wellness programs, and health insurance union members.
Quantifiable outcome
- Brain infarction cases reduced to approximately 1/3 after 7 years of service at one health insurance union
- +3 more outcomes
Companies that use Amine Pharma
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Amine Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Amine Pharma partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered strategic, core and major.
- Innovation Infusion Japan (i2.JP)strategicHealthcare open innovation network sponsored by AstraZeneca that connects startups, medical professionals, local governments, academia, and private companies to solve healthcare problems. Amine Pharma participates as a partner company.
- Chiba University Graduate School of Pharmaceutical Sciences, Medical Pharmacy Laboratory (千葉大学 大学院薬学研究院 医療薬学研究室)coreIndustry-academia research partnership for brain infarction biomarker development. Professor Ituko Ishii leads the laboratory collaborating on the A6C technology. This partnership produced the core research foundation for the brain infarction risk marker.
- Chiba Science University, Pathological Biochemistry Laboratory (千葉科学大学 薬学部 病態生化学研究室)coreIndustry-academia partnership led by Professor Kashiwagi for continued research collaboration on acrolein biochemistry and stroke prevention compounds.
- Koto Microorganism Laboratory (株式会社江東微生物研究所)majorClinical testing company handling sample processing for brain infarction risk assessment services in the Kanto region.
- Saitama Higashiwa Pharmaceutical (埼京東和薬品株式会社)majorClinical testing company partner for service distribution and sample processing.
- Sanritsu (株式会社サンリツ)majorClinical testing company partner for service distribution and sample processing.
- Medic (株式会社メディック)majorClinical testing company partner for service distribution and sample processing.
- Hoken Kagaku Kenkyuujo (株式会社保健科学研究所)majorClinical testing company partner for service distribution and sample processing.
- SRL (株式会社エス・アール・エル)majorClinical testing company partner for service distribution and sample processing.
- Nihon Medical Science Research Institute (株式会社日本医学臨床検査研究所)majorClinical testing company partner handling sample processing and testing services.
- BML (株式会社ビー・エム・エル)majorClinical testing company partner for service distribution and sample processing.
- Alp (株式会社アルプ)majorClinical testing company partner for service distribution and sample processing, based in Ishikawa.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Amine Pharma competitors and assessment
Company assessmentBroad incumbents
- Eiken Chemical: Japanese IVD manufacturer focused on clinical chemistry, immunological testing, and genetic diagnostics. Comparable as both develop proprietary IVD products for the Japanese clinical market and distribute through medical institutions and clinical labs.
- Denka Company: Japanese chemical and IVD manufacturer (formerly Denka Seiken) producing diagnostic reagents and testing kits. Comparable as both operate in the Japanese IVD market, with Denka supplying diagnostic products to clinical labs and medical institutions.
- Quest Diagnostics: US clinical laboratory giant providing comprehensive diagnostic testing services including cardiovascular and neurological biomarker panels. Comparable in business model as both operate clinical diagnostic testing services serving medical institutions, though at vastly different scale and geographies.
- Tosoh Corporation: Japanese chemical manufacturer with a diagnostics division producing clinical chemistry and immunoassay reagents. Comparable as both supply IVD products into the Japanese clinical diagnostics ecosystem through clinical lab channels.
- Sysmex Corporation: Japanese in-vitro diagnostics leader with broad portfolio in hematology, immunology, and clinical chemistry. Comparable as both companies develop and distribute clinical diagnostic products through medical institutions in Japan, though Sysmex operates at vastly greater scale and across multiple diagnostic categories.
- H.U. Group Holdings: Parent company of SRL, one of Japan's largest clinical laboratory groups and a direct channel partner of Amine Pharma. Comparable as both operate in the Japanese clinical diagnostics ecosystem, with H.U. Group providing the lab infrastructure that processes A6C samples.
- BML: One of Japan's largest independent clinical laboratory companies and a channel partner for A6C sample processing. Comparable as both provide clinical diagnostic testing services to Japanese medical institutions and health insurance programs.
- Labcorp: US clinical laboratory company offering broad diagnostic testing services including cardiovascular and neurology panels. Comparable as both provide clinical laboratory-based diagnostic testing to healthcare providers, with Labcorp operating at significantly larger scale and breadth.
Emerging players
- Quanterix: US-based neurology biomarker diagnostics company using ultra-sensitive single-molecule array technology. Comparable as both develop novel biomarker-based diagnostics for neurological conditions, though Quanterix focuses on Alzheimer's and neurodegeneration rather than stroke risk.
- C2N Diagnostics: US-based diagnostics company that developed PrecivityAD, a blood-based Alzheimer's disease diagnostic test. Comparable as both are developing blood-based diagnostic tests for brain/neurological conditions through novel biomarker approaches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Amine Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amine Pharma leadership team
Management profileNumber of profiles
Profiles1 record
Amine Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amine Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amine Pharma
What does Amine Pharma do?
Amine Pharma operates the Cerebral Infarction Risk Assessment Service (A6C), a proprietary blood-based diagnostic that detects silent (asymptomatic) cerebral infarction with approximately 85% accuracy by measuring toxic acrolein, IL-6, and CRP levels and classifying patients into three risk tiers (low-risk, borderline, high-risk). The service is offered through partnered medical institutions and clinical testing laboratories as a standalone "Simple Type" test or as an add-on to comprehensive health checkups (人間ドック) and brain-specific examinations (脳ドック), and is also sold in bulk to corporate wellness programs and health insurance unions.
Is Amine Pharma a public or private company?
Amine Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Amine Pharma founded?
Amine Pharma was founded in 2009. It employs 101 to 250 people.
Where is Amine Pharma based?
Amine Pharma is headquartered in Chiba, Japan, in the Asia region.
How does Amine Pharma make money?
One revenue line is on record: brain Infarction Risk Assessment Testing.
Who are Amine Pharma's main competitors?
Broad incumbents on record are Eiken Chemical, Denka Company, Quest Diagnostics, Tosoh Corporation, Sysmex Corporation, H.U. Group Holdings, BML and Labcorp. Emerging players are Quanterix and C2N Diagnostics.
Does Amine Pharma have an API?
No public API is recorded for Amine Pharma.